Mylan’s Delamanid Launched in India, Treats Multidrug Resistant TB
Out of 10.4 million new tuberculosis (TB) cases globally, 2.8 million arise in India, according to WHO. In India, TB continues to take lives due to insufficient measures of supplying life-saving drugs. Growing drug resistance is worsening the picture and slowing down the cure rates.
Mylan’s anti-TB drug, Delamanid received marketing approval from the Drug Controller General of India (DCGI) – drug regulator of India. It is a new class of anti-TB drugs designed to treat multi-drug resistant TB (MDR) specifically. Delamanid is indicated for the treatment of pulmonary TB due to multi-drug resistant Mycobacterium strains.
The number of multidrug-resistant (MDR) and extensively drug resistant (XDR) TB cases is rising in India. Nearly 2.5 percent of the new TB cases arising in India are resistant either to rifampicin or both rifampicin and isoniazid – the two most commonly used main first-line anti-TB drugs.
Last year, the government launched Bedaquiline drug to treat MDR TB for 600 patients across India. It was the first drug launched after four decades to treat TB. It has been made available in five cities– Delhi, Mumbai, Chennai, Guwahati, and Ahmedabad.
Now, Delamanid is launched for those patients who are irresponsive to most of the first or second line of TB treatment. Delamanid 50mg is believed to benefit people with MDR strains of TB. Japan’s Otsuka Pharmaceutical developed Delamanid. In 2014, it received approval in Europe, Japan, and South Korea.
Hinduja Hospital in Mumbai had already made the drug available for those patients who have stopped responding to most of the first and second line drugs.
Stopping the treatment in between and lack of compliance are the major reason of transforming an uncomplicated TB into a drug resistant form.
India is aligned to the WHO’s ‘End TB Strategy’ to make the world TB free. The new anti TB drugs like Delamanid and Bedaquiline is believed to reduce the number of TB cases in India, but the efforts to make patients aware of the diagnosis and compliance to drugs are necessary.